Greenrise Global Brands Inc. (Frankfurt: C4T) (ISIN: CA39540L1085) (CSE: XCX) (“Greenrise Global”), a distributor of medical and CBD wellness cannabis products in Germany, announces that its wholly-owned subsidiary, AMP Alternative Medical Products GmbH (“AMP”) and Eurox Pharma GmbH (“Eurox”), one of Europe’s leading medical cannabis companies, the beginning of sales of Dronabinol produced in Germany by Eurox.
Dronabinol is pure Tetrahydrocannabinol (THC) and is registered as an active pharmaceutical ingredient (API) and has been registered for sale with the appropriate authorities in Germany. Doctors and pharmacists can find more information about the product or order on AMP’s website: https://amp-eu.com/doccheck-login/
AMP and Eurox entered into a non-exclusive marketing and distribution agreement for Dronabinol for sale in pharmacies beginning in February 2022. In preparation for sales to begin at pharmacies, AMP has trained its national sales team on the benefits of Dronabinol for patients to doctors and preparation methods for pharmacists.
Eurox was one of the first medical cannabis companies to produce Dronabinol made in Germany at one of Europe’s largest GMP facilities located in Hessen, Germany and controls the entire supply chain from cultivation, production to distribution ensuring a stable and efficient supply to its customers.
Neil Smith, Chairman of Eurox commented, “If you’re a believer in the ‘Made in Germany‘, then that means Eurox. AMP’s focus on serving German patients and its national sales coverage make them a perfect partner for us.”
Dr. Stefan Feuerstein, President and Director of Greenrise Global and Managing Director of AMP, “The German market is gravitating towards pharmaceutical products as health authorities are increasing their regulatory control to ensure patient safety. Dronabinol is a well-established product in Germany, and we anticipate that it will be one of our strongest selling products this year.”